Journal of Enzyme Inhibition and Medicinal Chemistry · 2019 · 11 citations · 13 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryMolecular OncologyComputational Drug DiscoveryDrug Targeting StrategiesMelanoma PharmacotherapyTargeted Cancer TherapyBraf V600 MutationsMapk Pathway MutationsMapk SignalingMek InhibitionRaf-mek-erk SignalingSelectivityTargeted Inhibitor DesignTargeted Kinase Inhibition
BRAF belongs to the upstream portion of the MAPK pathway, which is involved in cell proliferation and survival. When mutations occur in BRAF, downstream MEK and ERK are phosphorylated irrespective of RAS, resulting in melanoma-like cancer. Over the years, small molecules targeting BRAFV600E have been discovered to be very effective melanoma drugs, but they are known to cause the BRAF paradox. Recently, it was shown that this paradox is caused by the heterodimer phenomenon of BRAF/CRAF. Here, we suggest one method by which paradoxical activation can be avoided by selectively inhibiting BRAFV600E and CRAF but not wild-type BRAF. From previous report of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl) aryl amide as a selective inhibitor of BRAFV600E and CRAF, we present compounds that offer enhanced selectivity and efficacy with the aid of molecular modelling.
13
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations
Medicine, Oncology, Pharmacology +14
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou, Kyung Song, Ivana Yen et al. · Nature · 2010 · 1.6K citations
Medicine, Cancer Biology, Oncology +15